Associations of lipoprotein subclasses with risk of all-cause and cardiovascular disease mortality in individuals with type 2 diabetes: A prospective cohort study.

AIM Although lipoproteins are well-established risk factors for cardiovascular disease (CVD) mortality, conventional measurements failed to identify lipoprotein particle sizes. This study aimed to investigate associations of lipoprotein subclasses categorized by particle sizes with risk of all-cause and CVD mortality in individuals with type 2 diabetes. METHODS This study included 6575 individuals with type 2 diabetes from the UK Biobank. Concentrations of very low-, low-, intermediate- and high-density lipoprotein [very-low-density lipoprotein (VLDL), low-density lipoprotein (LDL), intermediate-density lipoprotein and high-density lipoprotein (HDL)] particles in 14 subclasses and lipid constituents within each subclass were measured by quantitative nuclear magnetic resonance. Multivariable-adjusted Cox proportional-hazard regression models were used to estimate the hazard ratio (HR) for per standard deviation increment of log-transformed lipoprotein subclasses with risk of mortality. All p-values were adjusted by the false discovery rate method. RESULTS During a median follow-up of 11.4 years, 943 deaths were documented, including 310 CVD deaths. Small HDL particles were inversely associated with CVD mortality, with HR (95% CI) of 0.78 (0.69, 0.87), whereas very large and large HDL particles were positively associated with CVD mortality with HR (95% CI) of 1.28 (1.12, 1.45) and 1.19 (1.05, 1.35), respectively. A similar pattern was observed for all-cause mortality [small HDL particle (HR, 95% CI): 0.79, 0.74-0.85; large HDL particle: 1.15, 1.07-1.24; very large HDL particle: 1.26, 1.17-1.36]. For VLDL and LDL, very small VLDL particle was positively, while medium LDL particle was inversely associated with all-cause mortality, but not associated with CVD mortality. The pattern of association with all-cause and CVD mortality for cholesterol and triglyceride within lipoprotein particles was similar to those for lipoprotein particles themselves. CONCLUSIONS The associations between lipoprotein particles, particularly HDL particles, with all-cause and CVD mortality among patients with type 2 diabetes were significantly varied by particle sizes, highlighting the importance of particle size as a lipoprotein metric in mortality risk discrimination.

[1]  Yan V. Sun,et al.  Association Between High-Density Lipoprotein Cholesterol Levels and Adverse Cardiovascular Outcomes in High-risk Populations. , 2022, JAMA cardiology.

[2]  P. Elliott,et al.  Approaches to minimising the epidemiological impact of sources of systematic and random variation that may affect biochemistry assay data in UK Biobank. , 2020, Wellcome open research.

[3]  B. Nordestgaard,et al.  Novel Insights From Human Studies on the Role of High-Density Lipoprotein in Mortality and Noncardiovascular Disease. , 2020, Arteriosclerosis, thrombosis, and vascular biology.

[4]  G. Zhong,et al.  HDL-C is associated with mortality from all causes, cardiovascular disease and cancer in a J-shaped dose-response fashion: a pooled analysis of 37 prospective cohort studies , 2020, European journal of preventive cardiology.

[5]  Andres Metspalu,et al.  A metabolic profile of all-cause mortality risk identified in an observational study of 44,168 individuals , 2019, Nature Communications.

[6]  Chien-Jen Chen,et al.  Association of Diabetes With All-Cause and Cause-Specific Mortality in Asia , 2019, JAMA network open.

[7]  Jacob P. Kelly,et al.  High-Density Lipoprotein Particle Subfractions in Heart Failure With Preserved or Reduced Ejection Fraction. , 2019, Journal of the American College of Cardiology.

[8]  Manfred Spraul,et al.  Quantitative Lipoprotein Subclass and Low Molecular Weight Metabolite Analysis in Human Serum and Plasma by 1H NMR Spectroscopy in a Multilaboratory Trial. , 2018, Analytical chemistry.

[9]  M. Connelly,et al.  Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial. , 2018, Journal of clinical lipidology.

[10]  R. Collins,et al.  Lipids, Lipoproteins, and Metabolites and Risk of Myocardial Infarction and Stroke , 2018, Journal of the American College of Cardiology.

[11]  J. Lane,et al.  Night Shift Work, Genetic Risk, and Type 2 Diabetes in the UK Biobank , 2018, Diabetes Care.

[12]  W. März,et al.  High-Density Lipoprotein Subclasses, Coronary Artery Disease, and Cardiovascular Mortality. , 2017, Clinical chemistry.

[13]  P. Barter,et al.  HDL cholesterol concentration or HDL function: which matters? , 2017, European heart journal.

[14]  B. Nordestgaard,et al.  Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies , 2017, European heart journal.

[15]  Debbie A Lawlor,et al.  Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Large-Scale Epidemiology: A Primer on -Omic Technologies , 2017, American journal of epidemiology.

[16]  A. Berghold,et al.  Serum Concentration of HDL Particles Predicts Mortality in Acute Heart Failure Patients , 2017, Scientific Reports.

[17]  Cathie Sudlow,et al.  Algorithms for the Capture and Adjudication of Prevalent and Incident Diabetes in UK Biobank , 2016, PloS one.

[18]  S. Fazio,et al.  HDL Particle Size and Functional Heterogeneity. , 2016, Circulation research.

[19]  W. Kraus,et al.  High-density lipoprotein subclass measurements improve mortality risk prediction, discrimination and reclassification in a cardiac catheterization cohort. , 2016, Atherosclerosis.

[20]  F. Sacks,et al.  Novel Pathways of Apolipoprotein A-I Metabolism in High-Density Lipoprotein of Different Sizes in Humans , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[21]  K. Rye,et al.  HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export. , 2015, Circulation research.

[22]  P. Elliott,et al.  UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age , 2015, PLoS medicine.

[23]  Pasi Soininen,et al.  Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. , 2015, Circulation. Cardiovascular genetics.

[24]  Toomas Haller,et al.  Biomarker Profiling by Nuclear Magnetic Resonance Spectroscopy for the Prediction of All-Cause Mortality: An Observational Study of 17,345 Persons , 2014, PLoS medicine.

[25]  Yu-ming Chen,et al.  Effects of blood triglycerides on cardiovascular and all-cause mortality: a systematic review and meta-analysis of 61 prospective studies , 2013, Lipids in Health and Disease.

[26]  Zahi A Fayad,et al.  Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. , 2012, Circulation.

[27]  Ewout W Steyerberg,et al.  Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers , 2011, Statistics in medicine.

[28]  Trevor Hastie,et al.  Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.

[29]  Costantina Manes,et al.  Endothelial-Vasoprotective Effects of High-Density Lipoprotein Are Impaired in Patients With Type 2 Diabetes Mellitus but Are Improved After Extended-Release Niacin Therapy , 2010, Circulation.

[30]  Y. Benjamini,et al.  Adaptive linear step-up procedures that control the false discovery rate , 2006 .

[31]  Judith D. Goldberg,et al.  Applied Survival Analysis , 1999, Technometrics.

[32]  S. Haffner.  Management of Dyslipidemia in Adults With Diabetes , 1998, Diabetes Care.

[33]  P. Barter,et al.  Dysfunctional HDL and atherosclerotic cardiovascular disease , 2016, Nature Reviews Cardiology.

[34]  W. März,et al.  Low-density lipoprotein particle diameter and mortality: the Ludwigshafen Risk and Cardiovascular Health Study. , 2015, European heart journal.

[35]  P. Joshi,et al.  HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the Lipoprotein Investigators Collaborative. , 2015, European heart journal.

[36]  K. Parhofer,et al.  Diabetic dyslipidemia. , 2014, Metabolism: clinical and experimental.